WS Investor
02 Nov 2026, 18:53
Axsome Therapeutics Falls 9.6% Despite 52% Revenue Growth as Spending Remains Elevated
Axsome Therapeutics (NASDAQ: AXSM) shares fell about 9.6% despite reporting strong third-quarter 2026 product growth and a sharply narrower net loss.
Total net product revenue increased 52% year over year to $259.7 million, surpassing a $1 billion annualized run rate. AUVELITY remained the main growth driver, with sales rising 53% to $207.6 million.
SUNOSI revenue increased 47% to $48.2 million, including $8.5 million of milestone revenue, while SYMBRAVO sales rose 88% to $3.9 million from a relatively small base.
The bottom line improved substantially. Net loss narrowed to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, a year earlier. However, operating expenses remained high. R&D expense increased to $50.6 million from $40.2 million, while SG&A climbed to $203.1 million from $150.2 million as the company continued to invest in clinical programs and commercialization.
Axsome ended the quarter with $313.9 million in cash and cash equivalents, compared with $322.9 million at the end of 2025. Management said existing liquidity should be sufficient to fund operations through cash flow positivity under its current plan.
The company also initiated the Phase 3 SUMMIT trial of AXS-05 in smoking cessation, adding another potential indication to its CNS pipeline.
The 9.6% decline appears to reflect investor concern over the company’s still-heavy spending profile and the quality of some reported growth, including milestone revenue within SUNOSI, rather than weakness in underlying product demand. AUVELITY growth remains strong and losses are narrowing, but the market reaction suggests investors were looking for faster operating leverage or a cleaner path toward sustained profitability.
Axsome Therapeutics (NASDAQ: AXSM) shares fell about 9.6% despite reporting strong third-quarter 2026 product growth and a sharply narrower net loss.
Total net product revenue increased 52% year over year to $259.7 million, surpassing a $1 billion annualized run rate. AUVELITY remained the main growth driver, with sales rising 53% to $207.6 million.
SUNOSI revenue increased 47% to $48.2 million, including $8.5 million of milestone revenue, while SYMBRAVO sales rose 88% to $3.9 million from a relatively small base.
The bottom line improved substantially. Net loss narrowed to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, a year earlier. However, operating expenses remained high. R&D expense increased to $50.6 million from $40.2 million, while SG&A climbed to $203.1 million from $150.2 million as the company continued to invest in clinical programs and commercialization.
Axsome ended the quarter with $313.9 million in cash and cash equivalents, compared with $322.9 million at the end of 2025. Management said existing liquidity should be sufficient to fund operations through cash flow positivity under its current plan.
The company also initiated the Phase 3 SUMMIT trial of AXS-05 in smoking cessation, adding another potential indication to its CNS pipeline.
The 9.6% decline appears to reflect investor concern over the company’s still-heavy spending profile and the quality of some reported growth, including milestone revenue within SUNOSI, rather than weakness in underlying product demand. AUVELITY growth remains strong and losses are narrowing, but the market reaction suggests investors were looking for faster operating leverage or a cleaner path toward sustained profitability.
